VIKING THERAPEUTICS INC (1VKTX.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1VKTX - US92686J1060 - Common Stock
1VKTX.MI Key Statistics, Chart & Performance
The current stock price of 1VKTX.MI is 27.525 EUR. In the past month the price decreased by -9.62%.
1VKTX.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 66.13 | 43.32B | ||
| ARGX.BR | ARGENX SE | 65.51 | 42.91B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.53B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.59B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.74B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.86B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.87B | ||
| NANO.PA | NANOBIOTIX | N/A | 841.84M | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| IVA.PA | INVENTIVA SA | N/A | 779.35M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20 | 666.67M |
Related stock screener links
About 1VKTX.MI
Company Profile
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 50 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
Company Info
VIKING THERAPEUTICS INC
9920 Pacific Heights Blvd, Suite 350
San Diego CALIFORNIA US
Employees: 50
Phone: 18587044660
VIKING THERAPEUTICS INC / 1VKTX.MI FAQ
What does 1VKTX do?
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California and currently employs 50 full-time employees. The company went IPO on 2015-04-29. Its clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptors for the potential treatment of various metabolic disorders. The company is evaluating an oral formulation of VK2735 in a Phase II trial. The company is also developing VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders. Its newest program is evaluating a series of internally developed dual amylin and calcitonin receptor agonists for the treatment of obesity and other metabolic disorders. In the rare disease space, it is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy.
What is the stock price of VIKING THERAPEUTICS INC today?
The current stock price of 1VKTX.MI is 27.525 EUR. The price decreased by -17.06% in the last trading session.
Does VIKING THERAPEUTICS INC pay dividends?
1VKTX.MI does not pay a dividend.
What is the ChartMill technical and fundamental rating of 1VKTX stock?
1VKTX.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Which stock exchange lists 1VKTX stock?
1VKTX.MI stock is listed on the Euronext Milan exchange.
Can you provide the number of employees for VIKING THERAPEUTICS INC?
VIKING THERAPEUTICS INC (1VKTX.MI) currently has 50 employees.
1VKTX.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1VKTX.MI.
1VKTX.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1VKTX.MI. No worries on liquidiy or solvency for 1VKTX.MI as it has an excellent financial health rating, but there are worries on the profitability.
1VKTX.MI Financial Highlights
Over the last trailing twelve months 1VKTX.MI reported a non-GAAP Earnings per Share(EPS) of -1.8. The EPS decreased by -127.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.11% | ||
| ROE | -33.29% | ||
| Debt/Equity | 0 |
1VKTX.MI Forecast & Estimates
23 analysts have analysed 1VKTX.MI and the average price target is 81.07 EUR. This implies a price increase of 194.54% is expected in the next year compared to the current price of 27.525.